Search

Your search keyword '"Ye, Jing Christine"' showing total 40 results
Start Over Author "Ye, Jing Christine"
40 results on '"Ye, Jing Christine"'

4. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

Author

Rodriguez-Otero, Paula, Usmani, Saad, Cohen, Adam D, van de Donk, Niels W C J, Leleu, Xavier, Gállego Pérez-Larraya, Jaime, Manier, Salomon, Nooka, Ajay K, Mateos, Maria Victoria, Einsele, Hermann, Minnema, Monique, Cavo, Michele, Derman, Benjamin A, Puig, Noemi, Gay, Francesca, Ho, P Joy, Chng, Wee-Joo, Kastritis, Efstathios, Gahrton, Gösta, Weisel, Katja, Nagarajan, Chandramouli, Schjesvold, Fredik, Mikhael, Joseph, Costa, Luciano, Raje, Noopur S, Zamagni, Elena, Hájek, Roman, Weinhold, Niels, Yong, Kwee, Ye, Jing Christine, Sidhana, Surbhi, Merlini, Giampaolo, Martin, Tom, Lin, Yi, Chari, Ajai, Popat, Rakesh, and Kaufman, Jonathan L

Published
2024
Full Text
View/download PDF

5. Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy

Author

Manzar, Gohar S., Dudzinski, Stephanie O., Yoder, Alison K., Seo, Aaron, Nasr, Lewis F., Rafei, Hind, Becnel, Melody R., Patel, Krina K., Lee, Hans C., Kaufman, Gregory P., Gaballa, Mahmoud M., Ye, Jing Christine, Saini, Neeraj, Thomas, Sheeba K., Amini, Behrang, Orlowski, Robert Z., Dabaja, Bouthaina S., Pinnix, Chelsea C., Gunther, Jillian R., Wu, Susan Y., and Fang, Penny Q.

Published
2024
Full Text
View/download PDF

6. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

Author

Gordan, Lucio Navarro, Tan, Carlyn Rose, Vescio, Robert, Ye, Jing Christine, Schinke, Carolina, Medhekar, Rohan, Fu, Alex Z., Lafeuille, Marie-Hélène, Thompson-Leduc, Philippe, Khare, Vipin, Reitan, John, Milkovich, Gary, Kaila, Shuchita, Davies, Faith, and Usmani, Saad Z.

Published
2024
Full Text
View/download PDF

9. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.

Author

Bumma, Naresh, Richter, Joshua, Jagannath, Sundar, Lee, Hans C., Hoffman, James E., Suvannasankha, Attaya, Zonder, Jeffrey A., Shah, Mansi R., Lentzsch, Suzanne, Baz, Rachid, Maly, Joseph J., Namburi, Swathi, Pianko, Matthew J., Ye, Jing Christine, Wu, Ka Lung, Silbermann, Rebecca, Min, Chang-Ki, Vekemans, Marie-Christiane, Munder, Markus, and Byun, Ja Min

Published
2024
Full Text
View/download PDF

10. Lenalidomide in the treatment of anti‐myelin‐associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose

Author

Stino, Amro M., primary, Bumma, Naresh, additional, Smith, Rachel, additional, Davalos, Long, additional, Allen, Jeff, additional, Ye, Jing Christine, additional, Pianko, Matthew, additional, Campagnaro, Erica, additional, Fierro, Cassandra, additional, Awad, Abdelrahman, additional, Murdock, Ben, additional, Pietrzak, Maciej, additional, Loszanski, Gerard, additional, Kline, David M., additional, Efebera, Yvonne, additional, and Elsheikh, Bakri, additional

Published
2023
Full Text
View/download PDF

11. POSTER: MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study

Author

Gordan, Lucio, primary, Tan, Carlyn Rose, additional, Vescio, Robert, additional, Ye, Jing Christine, additional, Schinke, Carolina, additional, Medhekar, Rohan, additional, Fu, Alex Z., additional, Lafeuille, Marie-Hélène, additional, Thompson-Leduc, Philippe, additional, Khare, Vipin, additional, Reitan, John, additional, Milkovich, Gary, additional, Kaila, Shuchita, additional, Davies, Faith, additional, and Usmani, Saad Z., additional

Published
2023
Full Text
View/download PDF

12. Progression-Free Survival of Daratumumab vs. Bortezomib Triplet Combination with Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

Author

Gordan, Lucio, primary, Tan, Carlyn Rose, additional, Vescio, Robert, additional, Ye, Jing Christine, additional, Schinke, Carolina, additional, Medhekar, Rohan, additional, Fu, Alex Z., additional, Lafeuille, Marie-Hélène, additional, Thompson-Leduc, Philippe, additional, Khare, Vipin, additional, Reitan, John, additional, Milkovich, Gary, additional, Kaila, Shuchita, additional, Davies, Faith, additional, and Usmani, Saad Z., additional

Published
2023
Full Text
View/download PDF

13. P-328 Talquetamab vs real-world physician's choice of therapy (RWPC): comparative efficacy in patients (pts) with triple-class exposed (TCE) relapsed/ refractory multiple myeloma (RRMM)

Author

Ye, Jing Christine, primary, Biran, Noa, additional, Nair, Sandhya, additional, Lin, Xiwu, additional, Qi, Keqin, additional, Londhe, Anil, additional, Ammann, Eric, additional, Renaud, Thomas, additional, Kane, Colleen, additional, Parekh, Trilok, additional, Gray, Kathleen, additional, Peterson, Steve, additional, and Costa, Luciano, additional

Published
2023
Full Text
View/download PDF

14. NSO-02 Characteristics of multiple myeloma patients with central nervous system involvement

Author

Chen, Jessica, primary, Richards, Tiffany, additional, Allen, Christy, additional, Jiang, Yue, additional, Bendig, Courtney, additional, Morphey, Ashley, additional, Cuellar, Elizabeth, additional, Knight, Sarah, additional, Ighovoyivwi, Efe, additional, Lu, Rebecca, additional, Lin, Pei, additional, Amini, Behrang, additional, Gaballa, Mahmoud, additional, Lee, Hans, additional, Manasanch, Elisabet, additional, Patel, Krina, additional, Thomas, Sheeba, additional, Ye, Jing Christine, additional, Dabaja, Bouthain, additional, Pinnix, Chelsea, additional, Fang, Penny, additional, Gunther, Jill, additional, Orlowski, Robert, additional, Weber, Donna, additional, and Becnel, Melody, additional

Published
2023
Full Text
View/download PDF

15. P-115 Progression-free survival of daratumumab vs. bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: a chart review study

Author

Gordan, Lucio, primary, Tan, Carlyn Rose, additional, Vescio, Robert, additional, Ye, Jing Christine, additional, Schinke, Carolina, additional, Medhekar, Rohan, additional, Fu, Alex, additional, Lafeuille, Marie-Helene, additional, Thompson-Leduc, Philippe, additional, Khare, Vipin, additional, Reitan, John, additional, Milkovich, Gary, additional, Kaila, Shuchita, additional, Davies, Faith, additional, and Usmani, Saad, additional

Published
2023
Full Text
View/download PDF

16. MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study

Author

Gordan, Lucio, primary, Tan, Carlyn Rose, additional, Vescio, Robert, additional, Ye, Jing Christine, additional, Schinke, Carolina, additional, Medhekar, Rohan, additional, Fu, Alex Z., additional, Lafeuille, Marie-Hélène, additional, Thompson-Leduc, Philippe, additional, Khare, Vipin, additional, Reitan, John, additional, Milkovich, Gary, additional, Kaila, Shuchita, additional, Davies, Faith, additional, and Usmani, Saad Z., additional

Published
2023
Full Text
View/download PDF

17. P-023 Talquetamab, a G protein–coupled receptor family C group 5 member D × CD3 bispecific antibody, in relapsed/refractory multiple myeloma: efficacy and safety of patient subgroups from monumenTAL-1

Author

Krishnan, Amrita, primary, Costa, Luciano, additional, Schinke, Carolina, additional, Karlin, Lionel, additional, Morillo, Daniel, additional, Martinez-Chamorro, Carmen, additional, Ye, Jing Christine, additional, Chari, Ajai, additional, Moreau, Philippe, additional, Caers, Jo, additional, Jakubowiak, Andrzej, additional, Campagna, Michela, additional, Masterson, Tara, additional, Hilder, Brandi, additional, Tolbert, Jaszianne, additional, Renaud, Thomas, additional, Smit, M. Damiette, additional, Heuck, Christoph, additional, and Minnema, Monique, additional

Published
2023
Full Text
View/download PDF

18. Lenalidomide in the treatment of anti‐myelin‐associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose.

Author

Stino, Amro M., Bumma, Naresh, Smith, Rachel, Davalos, Long, Allen, Jeff, Ye, Jing Christine, Pianko, Matthew, Campagnaro, Erica, Fierro, Cassandra, Awad, Abdelrahman, Murdock, Ben, Pietrzak, Maciej, Loszanski, Gerard, Kline, David M., Efebera, Yvonne, and Elsheikh, Bakri

Subjects
LENALIDOMIDE, NEUROPATHY, THROMBOEMBOLISM, DISEASE duration, CLINICAL drug trials
Abstract

Background: Anti‐myelin‐associated glycoprotein (MAG) neuropathy is a debilitating demyelinating polyneuropathy with no approved therapies. Our primary objective was to ascertain lenalidomide safety and maximum tolerated dose (MTD) in anti‐MAG neuropathy. Methods: This phase 1b, open‐label, single‐arm, dose‐finding trial was conducted from 2019 through 2022. The original design included a dose‐escalation/extension phase followed by a dose‐expansion phase. Three doses of lenalidomide were evaluated: 10, 15, and 25 mg. The main outcome was the MTD. Results: Eleven patients enrolled (10 men), with a mean age of 67.6 years (SD = 6.18, range 58–77 years) and mean disease duration of 8.5 years (SD = 10.9, range 1–40 years). The study terminated early due to higher‐than‐expected non‐dose‐limiting toxicity venous thromboembolism (VTE) events. The calculated MTD was 25 mg (posterior mean of toxicity probability was 0.01 with a 95% credible interval of 0.00, 0.06), but a recommended phase 2 dose of 15 mg was advised. For secondary exploratory outcomes, only EQ‐5D (−0.95, 95% CI −1.81 to −0.09) and total IgM (−162 mg/dL, 95% CI −298 to −26) showed signs of improvement by month 12. Conclusions: Lenalidomide was associated with higher‐than‐expected VTE events in anti‐MAG neuropathy patients, despite a calculated MTD of 25 mg. A recommended phase 2 dose of 15 mg was advised. Lenalidomide did not improve disability or impairment at 12 months, although this study was not powered for efficacy. The risks of long term lenalidomide may outweigh benefit for patients with anti‐MAG neuropathy. Any future efficacy study should address VTE risk, as current myeloma guidelines appear inadequate. Trial Registration: Lenalidomide in Anti‐MAG Neuropathy: Phase 1b Study, ClinicalTrials.gov Identifier: NCT03701711, https://clinicaltrials.gov/ct2/show/NCT03701711. First submitted October 10, 2018. First patient enrolled in January 2019. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

Lee, Hans C., primary, Bumma, Naresh, additional, Richter, Joshua, additional, Dhodapkar, Madhav, additional, Hoffman, James E., additional, Suvannasankha, Attaya, additional, Zonder, Jeffrey, additional, Shah, Mansi R., additional, Lentzsch, Suzanne, additional, Maly, Joseph J., additional, Ye, Jing Christine, additional, Wu, Ka Lung, additional, Deveaux, Michelle, additional, Chokshi, Dhruti, additional, Boyapati, Anita, additional, Hazra, Anasuya, additional, Lorenc, Karen Rodriguez, additional, Kroog, Glenn, additional, Houvras, Yariv, additional, and Jagannath, Sundar, additional

Published
2023
Full Text
View/download PDF

20. S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Author

Touzeau, Cyrille, primary, Schinke, Carolina, additional, Minnema, Monique, additional, van de Donk, Niels W.C.J., additional, Rodríguez-Otero, Paula, additional, Mateos, Maria-Victoria, additional, Rasche, Leo, additional, Ye, Jing Christine, additional, Vishwamitra, Deeksha, additional, MA, Xuewen, additional, Qin, Xiang, additional, Campagna, Michela, additional, Masterson, Tara, additional, Hilder, Brandi, additional, Tolbert, Jaszianne, additional, Renaud, Thomas, additional, Goldberg, Jenna, additional, Heuck, Christoph, additional, and Chari, Ajai, additional

Published
2023
Full Text
View/download PDF

21. PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

Ye, Jing Christine, primary, Biran, Noa, additional, Nair, Sandhya, additional, Lin, Xiwu, additional, Qi, Keqin, additional, Londhe, Anil, additional, Ammann, Eric, additional, Renaud, Thomas, additional, Kane, Colleen, additional, Parekh, Trilok, additional, Gray, Kathleen, additional, Peterson, Steve, additional, and Costa, Luciano, additional

Published
2023
Full Text
View/download PDF

22. The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Author

Kumar, Shaji K, primary, Hofmeister, Craig C, additional, Biran, Noa, additional, Kaur, Gurbakhash, additional, Ye, Jing Christine, additional, Zonder, Jeffrey A., additional, Syed, Umar, additional, Yesil, Jennifer, additional, Woolley, Karen, additional, Mulligan, George, additional, and Cho, Hearn J., additional

Published
2022
Full Text
View/download PDF

25. Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Author

Jagannath, Sundar, Richter, Joshua, Dhodapkar, Madhav V., Hoffman, James E., Lee, Hans C., Suvannasankha, Attaya, Shah, Mansi R., Lentzsch, Suzanne, Zonder, Jeffrey A., Baz, Rachid, Maly, Joseph J., Namburi, Swathi, Wu, Ka Lung, Pianko, Matthew, Ye, Jing Christine, Silbermann, Rebecca, Min, Chang-Ki, Vekemans, Marie-Christiane, Munder, Markus, Byun, Ja Min, Lopez, Joaquín Martínez, DeVeaux, Michelle, Chokshi, Dhruti, Boyapati, Anita, Hazra, Anasuya, Rodriguez Lorenc, Karen, Kroog, Glenn S., Houvras, Yariv, and Bumma, Naresh

Published
2023
Full Text
View/download PDF

26. Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Author

Hoffman, James E., Bumma, Naresh, Richter, Joshua, Dhodapkar, Madhav V., Lee, Hans C., Suvannasankha, Attaya, Houde, Christiane A., Maly, Joseph J., Shah, Mansi R., Baz, Rachid, Namburi, Swathi, Wu, Ka Lung, Pianko, Matthew, Ye, Jing Christine, Lentzsch, Suzanne, Silbermann, Rebecca, Min, Chang-Ki, Vekemans, Marie-Christiane, Munder, Markus, Byun, Ja Min, Lopez, Joaquín Martínez, DeVeaux, Michelle, Ivanescu, Cristina, Rodriguez Lorenc, Karen, Kroog, Glenn S., Houvras, Yariv, Inocencio, Timothy J., Chi, Lei, Harnett, James, Ma, Qiufei, and Jagannath, Sundar

Published
2023
Full Text
View/download PDF

27. Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.

Author

Horwitz, Steven M., Feldman, Tatyana A., Ye, Jing Christine, Khodadoust, Michael S., Munoz, Javier, Hamlin, Paul A., Kim, Youn H., Wilcox, Ryan A., Patel, Manish R., Coffey, Greg, Innes, Alison, Betz, Andreas, Holland, Jaymes, Guzman, Cristina B., and Smith, Sonali M.

Abstract

AbstractIn this phase-2a study (NCT01994382), patients aged ≥18 years with relapsed/refractory peripheral T-cell lymphoma (PTCL; angioimmunoblastic T-cell lymphoma/T follicular helper [AITL/TFH], n = 29); PTCL-not otherwise specified [NOS], n = 11; and Other, n = 25) received 30 mg oral cerdulatinib, a reversible dual inhibitor of spleen tyrosine kinase and Janus kinase, twice daily in 28-day cycles until disease progression or unacceptable toxicity. Overall response rate (ORR) was 36.2% (12 complete responses [CR],9 partial responses [PR], and 14 stable disease); median time to response was 1.9 months. ORR was 51.9% for AITL/TFH (10 CR, 4 PR) and 31.8% for Other (2 CR, 5 PR); median duration of response was 12.9 and 5.3 months, respectively. The most common grade ≥3 treatment-emergent adverse events were asymptomatic amylase elevation (23.1%), anemia (20.0%), and asymptomatic lipase elevation (18.5%). These data suggest clinical activity and acceptable tolerability for cerdulatinib in patients with relapsed/refractory PTCL. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

29. Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Author

Bernal, Leon, primary, Nooka, Ajay, additional, Cole, Craig, additional, Heffner, Leonard T., additional, Ye, Jing Christine, additional, Vij, Ravi, additional, Chen, Zhengjia, additional, Zhang, Chao, additional, Rushton, John, additional, Munevver, Cinnar, additional, Lonial, Sagar, additional, and Kaufman, Jonathan L., additional

Published
2019
Full Text
View/download PDF

30. Liver Graft‐Versus‐Host Disease is associated with poor survival among allogeneic hematopoietic stem cell transplant recipients

Author

Modi, Dipenkumar, primary, Ye, Jing Christine, additional, Surapaneni, Malini, additional, Singh, Vijendra, additional, Chen, Wei, additional, Jang, Hyejeong, additional, Deol, Abhinav, additional, Ayash, Lois, additional, Alavi, Asif, additional, Ratanatharathorn, Voravit, additional, and Uberti, Joseph P., additional

Published
2019
Full Text
View/download PDF

31. The myeloma-developing regimens using genomics (MyDRUG) master protocol.

Author

Auclair, Daniel, primary, Anderson, Kenneth Carl, additional, Avigan, David, additional, Bianchi, Giada, additional, Biran, Noa, additional, Chaudhry, Maria, additional, Cho, Hearn J., additional, Furlong, Maggie, additional, Hofmeister, Craig C., additional, Kansagra, Ankit J., additional, Krishnan, Amrita Y., additional, Larsen, Jeremy Todd, additional, Orloff, Gregory Joshua, additional, Vij, Ravi, additional, Voorhees, Peter Michael, additional, Yee, Andrew Jenho, additional, Ye, Jing Christine, additional, Zonder, Jeffrey A., additional, Lonial, Sagar, additional, and Kumar, Shaji, additional

Published
2019
Full Text
View/download PDF

32. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.

Author

Hoylman, Emily, Brown, Anna, Perissinotti, Anthony J., Marini, Bernard L., Pianko, Matthew, Ye, Jing Christine, Campagnaro, Erica, and Nachar, Victoria R.

Subjects
MULTIPLE myeloma, MONOCLONAL antibodies, CANCER treatment, PROGRESSION-free survival, CLINICAL trials, DARATUMUMAB
Abstract

Daratumumab and elotuzumab have demonstrated improvements in overall response rates (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM). There is a lack of comparative clinical trials and an even larger lack of consensus on the optimal integration of these novel agents into the treatment paradigm. Clinical outcomes were compared retrospectively in 37 patients who received daratumumab before elotuzumab (dara-first, n = 23) and patients who received elotuzumab before daratumumab (elo-first, n = 14). ORR to the first monoclonal antibody was not different (dara-first 56.5% vs. elo-first 64.3%, p =.641). ORR to the second antibody differed when daratumumab was given second compared to when elotuzumab was given second (64.3% vs. 34.8%, respectively; p =.081). Cumulative PFS for elo-first was significantly longer than dara-first (22.67 months vs. 10.5 months, respectively; p =.001). Response rates to daratumumab may be preserved irrespective of sequence. However, response rates to elotuzumab may diminish with prior daratumumab exposure. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

34. The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).

Author

Hamlin, Paul A., primary, Cheson, Bruce D., additional, Farber, Charles Michael, additional, Feldman, Tatyana, additional, Fenske, Timothy S, additional, Hess, Brian T., additional, Khatcheressian, James L., additional, Miller, Carole Brennan, additional, Munoz, Javier, additional, Patel, Manish R., additional, Smith, Sonali M., additional, Smith, Stephen Douglas, additional, Stevens, Don A., additional, Ye, Jing Christine, additional, Steele, Andrew, additional, Pandey, Anjali, additional, Birrell, Matt, additional, Leeds, Janet, additional, Coffey, Greg, additional, and Curnutte, John T, additional

Published
2018
Full Text
View/download PDF

35. Tolerability and response of the novel SYK/JAK inhibitor cerdulatinib in a phase 2a study in relapsed/refractory peripheral t cell lymphoma (PTCL).

Author

Horwitz, Steven M., primary, Hamlin, Paul A., additional, Feldman, Tatyana, additional, Hess, Brian T., additional, Mato, Anthony R., additional, Munoz, Javier, additional, Patel, Manish R., additional, Ye, Jing Christine, additional, Steele, Andrew, additional, Pandey, Anjali, additional, Birrell, Matt, additional, Leeds, Janet, additional, Coffey, Greg, additional, and Curnutte, John T, additional

Published
2018
Full Text
View/download PDF

36. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).

Author

Schinke, Carolina D., Touzeau, Cyrille, Minnema, Monique C., van de Donk, Niels W.C.J., Rodríguez-Otero, Paula, Mateos, Maria-Victoria, Rasche, Leo, Ye, Jing Christine, Vishwamitra, Deeksha, Ma, Xuewen, Qin, Xiang, Campagna, Michela, Masterson, Tara J., Hilder, Brandi, Tolbert, Jaszianne A., Renaud, Thomas, Goldberg, Jenna, Heuck, Christoph, and Chari, Ajai

Published
2023
Full Text
View/download PDF

37. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.

Author

Lee, Hans C., Bumma, Naresh, Richter, Joshua Ryan, Dhodapkar, Madhav V., Hoffman, James E., Suvannasankha, Attaya, Zonder, Jeffrey A., Shah, Mansi R., Lentzsch, Suzanne, Maly, Joseph J., Ye, Jing Christine, Lung Wu, Ka, DeVeaux, Michelle, Chokshi, Dhruti, Boyapati, Anita, Hazra, Anasuya, Rodriguez-Lorenc, Karen, Kroog, Glenn Scott, Houvras, Yariv J., and Jagannath, Sundar

Published
2023
Full Text
View/download PDF

38. Tracking Karyotype Changes in Treatment-Induced Drug-Resistant Evolution.

Author

Ye JC and Heng HH

Subjects
Humans, Antineoplastic Agents therapeutic use, Antineoplastic Agents pharmacology, Evolution, Molecular, Phenotype, Drug Resistance, Neoplasm genetics, Karyotype, Neoplasms genetics, Neoplasms drug therapy, Karyotyping methods
Abstract

Karyotype coding, which encompasses the complete chromosome sets and their topological genomic relationships within a given species, encodes system-level information that organizes and preserves genes' function, and determines the macroevolution of cancer. This new recognition emphasizes the crucial role of karyotype characterization in cancer research. To advance this cancer cytogenetic/cytogenomic concept and its platforms, this study outlines protocols for monitoring the karyotype landscape during treatment-induced rapid drug resistance in cancer. It emphasizes four key perspectives: combinational analyses of phenotype and karyotype, a focus on the entire evolutionary process through longitudinal analysis, a comparison of whole landscape dynamics by including various types of NCCAs (including genome chaos), and the use of the same process to prioritize different genomic scales. This protocol holds promise for studying numerous evolutionary aspects of cancers, and it further enhances the power of karyotype analysis in cancer research., (© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)

Published
2024
Full Text
View/download PDF

39. The New Era of Cancer Cytogenetics and Cytogenomics.

Author

Ye JC and Heng HH

Subjects
Humans, Cytogenetic Analysis methods, Cytogenetics methods, Karyotyping methods, Mutation, Chromosome Aberrations, Genomics methods, Neoplasms genetics
Abstract

The promises of the cancer genome sequencing project, combined with various -omics technologies, have raised questions about the importance of cancer cytogenetic analyses. It is suggested that DNA sequencing provides high resolution, speed, and automation, potentially replacing cytogenetic testing. We disagree with this reductionist prediction. On the contrary, various sequencing projects have unexpectedly challenged gene theory and highlighted the importance of the genome or karyotype in organizing gene network interactions. Consequently, profiling the karyotype can be more meaningful than solely profiling gene mutations, especially in cancer where karyotype alterations mediate cellular macroevolution dominance. In this chapter, recent studies that illustrate the ultimate importance of karyotype in cancer genomics and evolution are briefly reviewed. In particular, the long-ignored non-clonal chromosome aberrations or NCCAs are linked to genome or chromosome instability, genome chaos is linked to genome reorganization under cellular crisis, and the two-phased cancer evolution reconciles the relationship between genome alteration-mediated punctuated macroevolution and gene mutation-mediated stepwise microevolution. By further synthesizing, the concept of karyotype coding is discussed in the context of information management. Altogether, we call for a new era of cancer cytogenetics and cytogenomics, where an array of technical frontiers can be explored further, which is crucial for both basic research and clinical implications in the cancer field., (© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)

Published
2024
Full Text
View/download PDF

40. Optical Genome Mapping: A Machine-Based Platform in Cytogenomics.

Author

Ye JC and Tang G

Subjects
Humans, Genomics methods, Chromosome Mapping methods
Abstract

Optical genome mapping (OGM) has generated excitement following decades of research and development. Now, commercially available technical platforms have been used to compare various other cytogenetic and cytogenomic technologies, including karyotype, microarrays, and DNA sequencing, with impressive results. In this chapter, using OGM as a case study, we advocate for a new trend in future cytogenomics, emphasizing the power of machine automation to deliver higher-quality cytogenomic data. By briefly discussing OGM, along with its major advantages and limitations, we underscore the importance of karyotype-based genomic research, from both a theoretical framework and a new technology perspective. We also call for the encouragement of further technological platform development for the future of cytogenetics and cytogenomics., (© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results